Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

This study represents one of the largest cohorts to date evaluating survivorship issues among LTS treated with ICIs. Among patients receiving ICIs for at least six months, nearly one-third experienced impaired QoL, primarily driven by psychological distress and FoP. Further research is needed to address survivorship care in this population.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-12-10
DOI
https://doi.org/10.3389/fimmu.2025.1693295
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

Bahadır Köylü, Tuba Ugur Tuzcu, Tülay Eren, Safa Can Efil et al.
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

Bahadır Köylü, Tuba Ugur Tuzcu, Tülay Eren, Safa Can Efil, S. Dogan, Taha Koray Şahin, Mevlüde İnanç, Saadettin Kılıçkap, Muslih Ürün, Ömer Dızdar, Osman Sütçüoğlu, Mustafa Erman, Mehmet Alı Nahıt Şendur, Sercan Aksoy, Arzu Yaşar, Erdem Göker, Mehmet Artaç, Öztürk Ateş, Fatih Selçukbırıcık, Fatih Atalah, Fadime Sinem Ardic, Ahmet Fatih Oruç, Atila Yıldırım, Sebahattin Çelik, Halil Göksel Güzel, Kadriye Erkan Turan, İsmail Oğuz Kara, Ayla Gökmen, Sedat Biter, Salih Tünbekici, Fatma Alev Türker, Deniz Can Güven, Banu Öztürk, Özlem Çınar Özdemir, İlknur Deliktaş Onur, Görkem Turhan, Ahmet Kürsad Disli, Aydın Acarbay, Cevat İlteriş Kıkılı, Akgün Karakök, Gamze Emin
article en

Abstract

This study represents one of the largest cohorts to date evaluating survivorship issues among LTS treated with ICIs. Among patients receiving ICIs for at least six months, nearly one-third experienced impaired QoL, primarily driven by psychological distress and FoP. Further research is needed to address survivorship care in this population.

Frontiers in ImmunologyVol. 16
Van Yüzüncü Yıl Üniversitesi (TR), Izmir University (TR), Koç University (TR), Ankara University (TR), Karadeniz Technical University (TR), University of Health Science (KH), Turkish Armed Forces (TR), Ege University (TR), Memorial Ankara Hospital (TR), Necmettin Erbakan University (TR), Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR), Antalya Eğitim ve Araştırma Hastanesi (TR), Hacettepe University Hospital (TR), Istinye University (TR), Sağlık Bilimleri Üniversitesi (TR), Cukurova University (TR), Istanbul Medeniyet University (TR), Hacettepe University (TR), Erciyes University (TR), Gazi University (TR)
European Society for Medical Oncology
Openalex Percentile: Top 45%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.